INCY Key Statistics, Chart & Performance
The current stock price of INCY is 106.87 USD. In the past month the price increased by 12.29%. In the past year, price increased by 51.5%.
INCY Latest News, Press Relases and Analysis
INCY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.38B |
Related stock screener links
About INCY
Company Profile
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,617 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Company Info
INCYTE CORP
1801 Augustine Cut-Off
Wilmington DELAWARE 19803 US
CEO: Herve Hoppenot
Employees: 2617
Phone: 13024986700
INCYTE CORP / INCY FAQ
What does INCY do?
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,617 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
What is the stock price of INCYTE CORP today?
The current stock price of INCY is 106.87 USD. The price increased by 0.9% in the last trading session.
Does INCYTE CORP pay dividends?
INCY does not pay a dividend.
What is the ChartMill technical and fundamental rating of INCY stock?
INCY has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the PE ratio for INCY stock?
The PE ratio for INCYTE CORP (INCY) is 16.65. This is based on the reported non-GAAP earnings per share of 6.42 and the current share price of 106.87 USD.
Would investing in INCYTE CORP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on INCY.
INCY Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to INCY. When comparing the yearly performance of all stocks, INCY is one of the better performing stocks in the market, outperforming 90.03% of all stocks.
INCY Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to INCY. Both the health and profitability get an excellent rating, making INCY a very profitable company, without any liquidiy or solvency issues.
INCY Financial Highlights
Over the last trailing twelve months INCY reported a non-GAAP Earnings per Share(EPS) of 6.42. The EPS increased by 575.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 24.69% | ||
| ROA | 18.78% | ||
| ROE | 25.55% | ||
| Debt/Equity | 0.01 |
INCY Forecast & Estimates
32 analysts have analysed INCY and the average price target is 101.7 USD. This implies a price decrease of -4.84% is expected in the next year compared to the current price of 106.87.
For the next year, analysts expect an EPS growth of 428.71% and a revenue growth 18.26% for INCY